^
Association details:
| Biomarker: | MET exon 14 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | elzovantinib (TPX-0022) (Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
Published date:
10/11/2020
Excerpt:
MET alterations included amplification (N=9), Δex14 (n=7) and fusion (n=2)....TPX-0022 is a novel MET/SRC/CSF1R inhibitor. TPX-0022 was generally well-tolerated. Responses were observed in Δex14 NSCLC and MET amplified GC and CRC.
Trial ID:
